Context Enterprise Value from 2010 to 2024

CNTX Stock

USD 1.36 0.03 2.16%

Context Therapeutics Enterprise Value yearly trend continues to be fairly stable with very little volatility. Enterprise Value will likely drop to about 3.4 M in 2024. Enterprise Value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. View All Fundamentals

Enterprise Value

First Reported

2010-12-31

Previous Quarter

3.6 M

Current Value

3.4 M

Quarterly Volatility

38.4 M

Credit Downgrade

Yuan Drop

Covid

Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.

Check out the analysis of Context Therapeutics Correlation against competitors.

For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Latest Context Therapeutics' Enterprise Value Growth Pattern

Below is the plot of the Enterprise Value of Context Therapeutics over the last few years. Enterprise Value (or EV) is usually referred to as Context Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Context Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of Context Therapeutics value than its market capitalization because it takes into account all of Context Therapeutics existing debt. It is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. Context Therapeutics' Enterprise Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Context Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 19.69 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Enterprise Value

Timeline

Context Enterprise Value Regression Statistics

	Arithmetic Mean	54,094,745
	Geometric Mean	39,962,313
	Coefficient Of Variation	71.04
	Mean Deviation	32,210,364
	Median	77,511,267
	Standard Deviation	38,426,405
	Sample Variance	1476.6T
	Range	102.5M
	R-Value	(0.77)
	Mean Square Error	638T
	R-Squared	0.60
	Significance	0.0007
	Slope	(6,648,828)
	Total Sum of Squares	20672.2T

Context Enterprise Value History

	2024	3.4 M
	2023	3.6 M
	2022	-25 M
	2021	-7.2 M
	2020	61.5 M

Other Fundumenentals of Context Therapeutics

	Enterprise Value Over E B I T D A
	Enterprise Value Multiple

Context Therapeutics Enterprise Value component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Good Will	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Debt	Net Invested Capital	Capital Stock	Net Working Capital
Total Assets		0.98	-0.07	-0.51	-0.39	0.04	0.08	-0.69	0.32	-0.55	0.97	-0.6	0.08	0.57	-0.02	-0.32	0.46	0.26	0.33
Total Stockholder Equity	0.98		0.06	-0.54	-0.44	0.04	-0.06	-0.83	0.27	-0.61	0.97	-0.73	-0.06	0.71	0.0	-0.44	0.55	0.41	0.44
Net Tangible Assets	-0.07	0.06		0.48	-0.02	-0.76	-0.6	-0.33	-0.88	0.38	0.14	-0.03	-0.6	0.5	-0.7	-0.88	0.76	0.89	0.88
Retained Earnings	-0.51	-0.54	0.48		0.31	-0.59	0.18	0.45	-0.77	0.7	-0.39	0.62	0.18	-0.32	-0.56	-0.36	0.25	0.18	0.35
Accounts Payable	-0.39	-0.44	-0.02	0.31		-0.32	-0.01	0.44	-0.26	0.28	-0.37	0.35	-0.01	-0.41	-0.37	0.2	-0.42	-0.17	-0.22
Long Term Debt	0.04	0.04	-0.76	-0.59	-0.32		0.36	-0.08	0.91	-0.64	-0.17	-0.36	0.36	-0.07	0.99	0.61	-0.46	-0.58	-0.6
Good Will	0.08	-0.06	-0.6	0.18	-0.01	0.36		0.27	0.39	-0.11	-0.08	0.21	1.0	-0.32	0.27	0.35	-0.25	-0.49	-0.35
Total Liab	-0.69	-0.83	-0.33	0.45	0.44	-0.08	0.27		-0.12	0.68	-0.7	0.9	0.27	-0.94	-0.07	0.62	-0.64	-0.67	-0.62
Deferred Long Term Liab	0.32	0.27	-0.88	-0.77	-0.26	0.91	0.39	-0.12		-0.71	0.1	-0.4	0.39	-0.07	0.86	0.66	-0.5	-0.63	-0.66
Short Long Term Debt	-0.55	-0.61	0.38	0.7	0.28	-0.64	-0.11	0.68	-0.71		-0.41	0.91	-0.11	-0.44	-0.61	-0.05	0.04	0.06	0.05
Total Current Assets	0.97	0.97	0.14	-0.39	-0.37	-0.17	-0.08	-0.7	0.1	-0.41		-0.56	-0.08	0.61	-0.2	-0.49	0.6	0.42	0.5
Short Term Debt	-0.6	-0.73	-0.03	0.62	0.35	-0.36	0.21	0.9	-0.4	0.91	-0.56		0.21	-0.72	-0.36	0.32	-0.3	-0.34	-0.32
Intangible Assets	0.08	-0.06	-0.6	0.18	-0.01	0.36	1.0	0.27	0.39	-0.11	-0.08	0.21		-0.32	0.27	0.35	-0.25	-0.49	-0.35
Common Stock	0.57	0.71	0.5	-0.32	-0.41	-0.07	-0.32	-0.94	-0.07	-0.44	0.61	-0.72	-0.32		-0.08	-0.7	0.73	0.82	0.7
Property Plant Equipment	-0.02	0.0	-0.7	-0.56	-0.37	0.99	0.27	-0.07	0.86	-0.61	-0.2	-0.36	0.27	-0.08		0.57	-0.43	-0.55	-0.57
Net Debt	-0.32	-0.44	-0.88	-0.36	0.2	0.61	0.35	0.62	0.66	-0.05	-0.49	0.32	0.35	-0.7	0.57		-0.94	-0.92	-1.0
Net Invested Capital	0.46	0.55	0.76	0.25	-0.42	-0.46	-0.25	-0.64	-0.5	0.04	0.6	-0.3	-0.25	0.73	-0.43	-0.94		0.86	0.95
Capital Stock	0.26	0.41	0.89	0.18	-0.17	-0.58	-0.49	-0.67	-0.63	0.06	0.42	-0.34	-0.49	0.82	-0.55	-0.92	0.86		0.92
Net Working Capital	0.33	0.44	0.88	0.35	-0.22	-0.6	-0.35	-0.62	-0.66	0.05	0.5	-0.32	-0.35	0.7	-0.57	-1.0	0.95	0.92

Click cells to compare fundamentals

About Context Therapeutics Financial Statements

Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' Enterprise Value, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Enterprise Value Over EBITDA	(0.14)	(0.14)
Enterprise Value Multiple	(0.14)	(0.14)
Enterprise Value	3.6 M	3.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC